Physician profile
Allison R Lander
NPI 1346271269
$4,932.82
in general payments reported to CMS, 2019-2025
36 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $213 · 2021: $686 · 2022: $306 · 2023: $377 · 2024: $1,052 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $833.42 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $465.16 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $447.15 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $359.12 | 2019-2021 | |
| Abbvie INC. | $303.13 | 2019-2024 | |
| Lilly USA, LLC | $262.01 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $233.46 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $229.30 | 2019-2024 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $193.40 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Pfizer INC. | $188.86 | 2019-2024 | |
| Glaxosmithkline, LLC. | $185.82 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.34 | 2019-2025 | Jascayd |
| Cleerly, INC. | $148.21 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.82 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $104.92 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.91 | 2019-2024 | Spravato |
| Eisai INC. | $82.88 | 2025 | |
| Sumitomo Pharma America, INC. | $65.11 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $63.45 | 2019-2024 | Eliquis |
| Teleflex LLC | $49.53 | 2023 | Urolift |
| Exact Sciences Corporation | $34.10 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $30.88 | 2021 | |
| Itamar Medical INC | $29.98 | 2022-2024 | Watchpatone |
| Amneal Pharmaceuticals LLC | $24.99 | 2025 | Unithroid |
| Medtronic, INC. | $24.09 | 2025 | Symplicity G3 |
| Aimmune Therapeutics, INC. | $23.70 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $23.64 | 2025 | |
| Gilead Sciences, INC. | $21.78 | 2025 | |
| Inspire Medical Systems, INC. | $20.78 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $19.85 | 2025 | |
| Tolmar, INC. | $19.21 | 2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $18.26 | 2025 | Tlando |
| Medtronic Vascular, INC. | $15.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.71 | 2021 | |
| Allergan, INC. | $12.49 | 2020 | |
| Optos, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.